Detection of Plasma DNA Methylation in Peripheral Blood from Patients with Hepatocellular Carcinoma


About this study

This study aims to investigate the utility of using plasma DNA methylation to detect measurable residual disease or early recurrence/progression of patients with hepatocellular carcinoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Adult, age >= 18

- Patients with resectable hepatocellular carcinoma

Exclusion Criteria:

- Females who are pregnant or attempt to become pregnant

- Patient with significant anemia (hemoglobin [Hb] < 7g/dL)

- Patient has known cancer outside of the liver 5 years prior to current blood
collection (not including basal cell or squamous cell skin cancers)

- Patient has had a biopsy to the target organ and/or lesion within 3 days before blood

- Patient has had an intervention to completely remove current target pathology

Eligibility last updated 8/2/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Nguyen Tran, M.D.

Open for enrollment

Contact information:

Nguyen Tran M.D.

More information


Publications are currently not available

Mayo Clinic Footer